Skip to main content
SpringerLink
Log in

Targeting HER2 in Advanced Breast Cancer

  • Protocol
  • First Online:
Book cover ErbB Receptor Signaling

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1652))

Abstract

Human epidermal growth factor receptor 2 (HER2) is a human oncogene that is amplified in approximately 20% of breast cancers, and portends a worse prognosis if not treated with anti-HER2 agents. The advent of targeted anti-HER2 therapies has dramatically improved disease control and survival in patients with metastatic HER2-positive breast cancer, and is now considered standard of care in the first-line setting and beyond. This review summarizes the currently available data on targeted anti-HER2 therapies from completed randomized phase III clinical trials, and briefly discusses emerging advances that will address unmet needs in metastatic HER2-positive breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Krishnamurti U, Silverman JF (2014) HER2 in breast cancer. Adv Anat Pathol 21:100–107

    Article  CAS  PubMed  Google Scholar 

  2. Yarden Y (2001) The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3–S8

    Article  CAS  PubMed  Google Scholar 

  3. Brennan PJ, Kumogai T, Berezov A, Murali R, Greene MI, Kumogai T (2000) HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene 19:6093–6101

    Article  CAS  PubMed  Google Scholar 

  4. Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol Off J Eur Soc Med Oncol 12(Suppl 1):S3–S8

    Article  Google Scholar 

  5. Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469–6487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kirouac DC, Du J, Lahdenranta J et al (2016) HER2+ cancer cell dependence on PI3K vs. MAPK signaling axes is determined by expression of EGFR, ERBB3 and CDKN1B. PLoS Comput Biol 12:e1004827

    Article  PubMed  PubMed Central  Google Scholar 

  7. Winstanley J, Cooke T, Murray GD et al (1991) The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63:447–450

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  CAS  PubMed  Google Scholar 

  9. Hudis CA (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357:39–51

    Article  CAS  PubMed  Google Scholar 

  10. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  11. Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792

    Article  CAS  PubMed  Google Scholar 

  12. Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149–156

    Article  CAS  PubMed  Google Scholar 

  13. Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29:264–271

    Article  CAS  PubMed  Google Scholar 

  14. Burstein HJ, Keshaviah A, Baron AD et al (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110:965–972

    Article  CAS  PubMed  Google Scholar 

  15. Guan Z, Xu B, DeSilvio ML et al (2013) Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 31:1947–1953

    Article  CAS  PubMed  Google Scholar 

  16. Gelmon KA, Boyle F, Bella K, et al. (2012) Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. | [Internet]. [cited 2014 Oct 21]; Available from: http://meetinglibrary.asco.org/content/102986-114

  17. Baselga J, Cortés J, Kim S-B et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119

    Article  CAS  PubMed  Google Scholar 

  18. Swain SM, Kim S-B, Cortés J, et al. (2014) Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC) [Internet]. [cited 2014 Oct 12]; Available from: http://www.esmo.org/Conferences/ESMO-2014-Congress/News-Articles/Final-Overall-Survival-Analysis-from-the-CLEOPATRA-Study-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer

  19. Gelmon KA, Boyle FM, Kaufman B et al (2015) Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol 33:1574–1583

    Article  CAS  PubMed  Google Scholar 

  20. Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724–734

    Article  CAS  PubMed  Google Scholar 

  21. Ellis P, Barrios C, Eiermann W, et al. (2015) Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. | 2015 ASCO Annual Meeting | Abstracts | Meeting Library [Internet]. [cited 2017 Jan 23]; Available from: http://meetinglibrary.asco.org/content/147990-156

  22. von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27:1999–2006

    Article  Google Scholar 

  23. Urruticoechea A, Rizwanullah M, Im S-A, et al. PHEREXA: Benefit for Second-Line Pertuzumab Questionable - The ASCO Post [Internet]. [cited 2017 Jan 30]; Available from: http://www.ascopost.com/issues/july-25-2016/pherexa-benefit-for-second-line-pertuzumab-questionable/

  24. Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–1130

    Article  CAS  PubMed  Google Scholar 

  25. André F, O’Regan R, Ozguroglu M et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580–591

    Article  PubMed  Google Scholar 

  26. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  CAS  PubMed  Google Scholar 

  27. Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Blackwell KL, Burstein HJ, Storniolo AM et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30:2585–2592

    Article  CAS  PubMed  Google Scholar 

  29. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924–934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Krop IE, Kim S-B, González-Martín A et al (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15:689–699

    Article  CAS  PubMed  Google Scholar 

  31. Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol 32:2078–2099

    Article  CAS  PubMed  Google Scholar 

  32. Wang L, Zhang Q, Zhang J et al (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11:248

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Gabos Z, Sinha R, Hanson J et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663

    Article  CAS  PubMed  Google Scholar 

  34. Pestalozzi BC, Zahrieh D, Price KN et al (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol 17:935–944

    Article  CAS  PubMed  Google Scholar 

  35. Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278–5286

    Article  PubMed  Google Scholar 

  36. Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543

    Article  CAS  PubMed  Google Scholar 

  37. Pivot X, Manikhas A, Zurawski B et al (2015) CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33:1564–1573

    Article  CAS  PubMed  Google Scholar 

  38. Baselga J, Cortes J, Im S-A et al (2014) Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32(33):3753–3761

    Article  CAS  PubMed  Google Scholar 

  39. Baselga J, Verma S, Ro J, et al. (2013) Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) [Internet]. [cited 2014 Nov 14]; Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1e9ae007-6c50-46e2-951f-4b825865e743&cKey=15187a93-e3d3-443c-81b5-24d4f5e7bf0d

  40. Lambert JM (2013) Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 76:248–262

    Article  CAS  PubMed  Google Scholar 

  41. Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15–29

    Article  CAS  PubMed  Google Scholar 

  42. Dokter W, Ubink R, van der Lee M et al (2014) Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform. Mol Cancer Ther 13:2618–2629

    Article  CAS  PubMed  Google Scholar 

  43. Verheijden G, Beusker P, Ubink R, et al. (2014) Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC). 2014 ASCO Annual Meeting, Abstracts, Meeting Library [Internet]. [cited 2014 Nov 11]; Available from: http://meetinglibrary.asco.org/content/131605-144

Download references

Acknowledgments

The authors wish to thank Dr. Sunil Verma, who contributed to a previous version of a review on HER2-positive breast cancer. We also thank Larissa Vos for manuscript preparation and assistance.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta and Cross Cancer Institute, 11560 University Avenue, Edmonton, AB, Canada, T6G 1Z2

    Xiaofu Zhu M.D., F.R.C.P.C. & Anil Abraham Joy M.D., F.R.C.P.C.

Authors
  1. Xiaofu Zhu M.D., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anil Abraham Joy M.D., F.R.C.P.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiaofu Zhu M.D., F.R.C.P.C. or Anil Abraham Joy M.D., F.R.C.P.C. .

Editor information

Editors and Affiliations

  1. Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada

    Zhixiang Wang

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Zhu, X., Joy, A.A. (2017). Targeting HER2 in Advanced Breast Cancer. In: Wang, Z. (eds) ErbB Receptor Signaling. Methods in Molecular Biology, vol 1652. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7219-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7219-7_4

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7218-0

  • Online ISBN: 978-1-4939-7219-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation